Laurus Labs Limited

rs,

April 27, 2023 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 The Listing Department National Stock Exchange of Indi

₹ 1,594

robust business model Financial Results ₹ Setting strong base for future growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to

26.4%

del Financial Results ₹ Setting strong base for future growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth

₹ 6,041

esults ₹ Setting strong base for future growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth  Successful execu

22%

ng base for future growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth  Successful execution of large purc

23%

e for future growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth  Successful execution of large purchase o

₹ 990

re growth* ESG-Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth  Successful execution of large purchase order with Big

16%

Ratings* ₹ 1,594 Cr EBITDA 26.4% Margins ₹ 6,041 Cr Revenues +22% 23% RoCE ₹ 990 Cr Capex 16% of revenue to support growth  Successful execution of large purchase order with Big Pharma  W

28%

s  Dedicated $100mn+ investment in CDMO  CDMO R&D & Animal Health API facilities on track  +28% Capacity expansion in small molecules to 7.5 mn Lts  CMO project Pipeline increased & Started new

10%

rted new Sterile lab  6,500+ employees, incl. 2300+ scientific team (R&D/Quality)  Invest up to 10% of profits on disruptive technologies.  ImmunoACT initiated Ph-II/III for CD19 CAR-T candidate.

43%

momentum across divisions % of Revenues CAGR FY18-23 Our Global Footprints* 1 2 3 4 API 43% CDMO 36% FDF 19% BIO 2% 7% 71% 1 114% 2 47% * Based on Geographical location of the Cu

36%

cross divisions % of Revenues CAGR FY18-23 Our Global Footprints* 1 2 3 4 API 43% CDMO 36% FDF 19% BIO 2% 7% 71% 1 114% 2 47% * Based on Geographical location of the Customer 1 Ba

“Multiple 2.7x 5.9x * + 40% CAGR Our Impact till date Expanded capabilities and Access new market opportunities     Leveraged LL’s Global Customer base for AOF and CDMO offerings Enhance technical expertise in enzymes and bio- catalysis and promoting their application in small molecule (clinical & commercial projects) Integrating Precision fermentation based solution.”

“However, our Q4 Baseline business seeing healthy momentum overall and project pipeline continues to scale up.”

“R&D center and Animal Health) on track to seize market opportunities  Bio: Delivered strong recovery with +31% YoY growth (+109% QoQ).”

Chemical - expertise

1

Chemical - expertise

Small molecules including HP APIs GMP intermediates, Chiral Chemistry, Peptides, Hazardous chemistry, Large scale – Chromatography incl. SMB, Cryogenic, Hydrogenation & Flow chemistry >> Offers Integrated approach Manufacturing & Quality Service Platform Technology 6 global regulatory agencies 940+ quality audits 208 patents granted 75+ successful launch across DP/DS > > Analytical Services Life Cycle Management Microbial offering incl. HPAPIs within CMO Regulatory filings services Packaging Bio – expertise: Precision Fermentation (r-protein Food, Bio catalysis large scale) Oral Dosage forms & Delivery systems Autologous technology: Cell therapy Applying expertise across end market Human Health (Rx brands+Generics) Animal Health Consumer Health Agro-Chem Food & Nutrition Enabled 200+ Global Clients 6 Innovators Making efficient use of technology platform and Manufacturing excellence in the target market Our Business outcome – delivering strong growth momentum across divisions % of Reve